ea0008p1 | Bone | SFE2004
Rogers A
, Clowes JA
, Gossiel F
, Peel N
, Eastell R
The vitamin D receptor (VDR) polymorphism, BsmI, has previously been associated with the efficacy of raloxifene therapy. The aim of this study was to examine associations between the BsmI and FokI polymorphisms of the VDR gene and bone density and bone turnover response to raloxifene. One hundred osteopenic postmenopausal women (ages 52 to 80 years, mean 64 years) were prescribed raloxifene (60mg/day) and calcium carbonate (500mg/day) for 48 weeks. Bone density at the lumbar s...